Roles of HIF and 2-Oxoglutarate dependent enzymes in controlling gene expression in hypoxia

Julianty Frost¹, Mark Frost¹, Michael Batie¹, Hao Jiang², and Sonia Rocha¹*

¹ Department of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology. University of Liverpool. L697ZB Liverpool. United Kingdom. Julianty.Frost@liverpool.ac.uk; Mark.Frost@liverpool.ac.uk; Michael.Batie@liverpool.ac.uk
² Centre for Gene Regulation and Expression. School of Life Sciences. University of Dundee. DD15EH. Dundee. United Kingdom; h.y.jiang@dundee.ac.uk.

* Correspondence: srocha@liverpool.ac.uk; Tel.: +44 (0)151 794 9084

Simple Summary: Hypoxia — reduction in oxygen availability — plays key roles in both physiological and pathological processes. Given the importance of oxygen for cell and organism viability, mechanisms to sense and respond to hypoxia are in place. A variety of enzymes utilise molecular oxygen, but of particular importance to oxygen sensing are the 2-oxoglutarate (2-OG) dependent dioxygenases (2-OGDs). Of these, Prolyl-hydroxylases have long been recognised to control the levels and function of Hypoxia Inducible Factor (HIF), a master transcriptional regulator in hypoxia, via their hydroxylase activity. However, recent studies are revealing that dioxygenases are involved in almost all aspects of gene regulation, including chromatin organisation, transcription and translation.

Abstract: Hypoxia — reduction in oxygen availability — plays key roles in both physiological and pathological processes. Given the importance of oxygen for cell and organism viability, mechanisms to sense and respond to hypoxia are in place. A variety of enzymes utilise molecular oxygen, but of particular importance to oxygen sensing are the 2-oxoglutarate (2-OG) dependent dioxygenases (2-OGDs). Of these, Prolyl-hydroxylases have long been recognised to control the levels and function of Hypoxia Inducible Factor (HIF), a master transcriptional regulator in hypoxia, via their hydroxylase activity. However, recent studies are revealing that dioxygenases are involved in almost all aspects of gene regulation, including chromatin organisation, transcription and translation. We highlight the relevance of HIF and 2-OG dioxygenases in the control of gene expression in response to hypoxia and their relevance to human cancers.

Keywords: hypoxia; 2-OG dioxygenases; chromatin; transcription, translation; cancer

1. Introduction

The importance of oxygen for energy production in multicellular organisms has been appreciated since the identification of the mechanism of oxidative phosphorylation located in the mitochondria. Reductions in oxygen availability, or hypoxia, are therefore either danger signals or a cue for physiological processes such as development. Given the importance of oxygen, cells have perfected mechanisms to sense and respond to hypoxia, in order to minimise damage, preserve energy and, when possible, adapt to the new oxygen supply normality.
The main transcription factor activated under low oxygen conditions, called Hypoxia Inducible Factor (HIF) was identified in 1992 [1]. HIF is composed of a heterodimer of HIF-α (of which there are 3 isoforms, HIF-1α, HIF-2α (encoded by the EPAS1 gene) and HIF3-α) and HIF-1β (encoded by the gene ARNT) [2]. HIFs control many genes, most of which are crucial for cell survival and adaptation to low oxygen conditions [2]. Under pathological conditions, such as cancer and altitude sickness, induction of some of these genes by the HIF transcription factors has been linked to disease progression and treatment resistance [3]. In addition, HIF can also be induced by non-oxygen dependent mechanisms, such as inflammation [4]. This is particularly relevant for human cancers, where hypoxia and inflammation often co-occur [5].

The mechanism leading to the activation of HIF was unravelled in 2001 [6,7]. HIF-α, under normal oxygen conditions, is continually transcribed and translated, but rapidly degraded by the ubiquitin dependent proteasomal system (Figure 1). Ubiquitination is promoted by the E3-ligase composed of Von Hippel-Lindau Tumor Suppressor (VHL) Ring-Box 1 (RBX1), Cullin 2 (CUL2) and Elongin B/C (ELOCB/C) [3]. VHL affinity toward HIF-α is dramatically increased by the presence of a specific post-translational modification. This modification is a proline hydroxylation (Figure 1), mediated by Prolyl-Hydroxylases (PHDs). PHDs are part of the 2-oxoglutarate (2-OG) dependent dioxygenase (2-OGD) superfamily of enzymes, requiring oxygen, iron and 2-OG for activity [8]. Mammals possess three PHDs, PHD2 (gene name EGLN1), PHD3 (gene name EGLN3) and PHD1 (gene name EGLN2) [6]. Biochemical characterisation revealed that PHDs have low affinity for molecular oxygen. Low affinity for molecular oxygen signifies that when oxygen availability is reduced, these enzymes are quickly inhibited, leading to HIF stabilisation and activation of target genes. PHD inhibition in hypoxia has resulted in them being termed molecular oxygen sensors in the cell [9]. Subsequently, many more 2-OGDs have been identified, most of which act independently of HIF but play a role in coordinating the cellular response to hypoxia. These include Factor Inhibiting HIF1 (FIH), Jumonji C (JmjC)-domain containing demethylases (JmjC demethylases) (which demethylate both histones and non-histone proteins), Ten-Eleven Translocation (TET) enzymes (mediators of DNA-demethylation), and RNA-demethylases (Box 1). Given the function of some of these enzymes, it is conceivable that hypoxia could influence all aspects of gene expression, from chromatin structure and epigenetics to RNA biology, translation and protein turnover (Figure 2). This perfectly equips the cell when faced with hypoxia. Under such conditions, the cell must make a coordinated effort to allow for restoration of oxygen homeostasis, while reducing energy expenditure if it is to survive.

Genetic models in several model organisms has helped identify the key roles of HIFs as well as 2-OGDs in development and disease (Sup. Table 1). Furthermore, genomic techniques such as chromatin immunoprecipitation followed by sequencing (ChIP-seq) RNA sequencing (RNA-seq), and Chromatin capture have more recently been used to understand how cells responds to changes in oxygen, but also in response to 2-OGD inhibition.
Figure 1. Regulation of HIF levels and activity in normoxia and hypoxia. Under normal oxygen conditions, **A**, normoxia, HIF-α is constantly hydroxylated by PHDs and FIH. PHD-mediated hydroxylation increases binding affinity with the tumour suppressor VHL, which promotes ubiquitination and degradation by the proteosome. As oxygen levels decrease, in mild hypoxia **B**, PHDs are inhibited, HIF-α is stabilised, though still hydroxylated by FIH, binds to HIF-1β and is able to induce transcription of certain target genes. With further reduction in oxygen levels, in severe hypoxia **C**, FIH is also inhibited and HIF is able to become fully active by the recruitment of co-activators such as p300.

In this review, we highlight the importance of oxygen sensing in coordinating an efficient response to hypoxia. We discuss the relevance of HIF transcription factors, and roles of 2-OGDs in controlling almost all aspects of gene expression from chromatin structure, to transcription, translation and post-translational modifications.

**Box1. 2-OGDs and their reported affinities for oxygen from *in vitro* assays**
### 2-OGD Type

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>$O_2$ $K_M$ (µM)</th>
<th>Potential $O_2$ sensor (Yes/No)</th>
<th>Substrate</th>
<th>Effect on gene expression in hypoxia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxylases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHD1</td>
<td>230</td>
<td>Y</td>
<td>Multiple</td>
<td>Y</td>
</tr>
<tr>
<td>PHD2</td>
<td>240*</td>
<td>Y</td>
<td>Multiple</td>
<td></td>
</tr>
<tr>
<td>PHD3</td>
<td>230</td>
<td>Y</td>
<td>Multiple</td>
<td></td>
</tr>
<tr>
<td>4-PHα1</td>
<td>40</td>
<td></td>
<td>Collagen</td>
<td></td>
</tr>
<tr>
<td>PAHX</td>
<td>93</td>
<td>Y</td>
<td>Isovaleryl CoA</td>
<td></td>
</tr>
<tr>
<td>CDO1</td>
<td>76</td>
<td>N</td>
<td>Taurine</td>
<td></td>
</tr>
<tr>
<td>FIH</td>
<td>110*</td>
<td>Y/N</td>
<td>Multiple</td>
<td>Y</td>
</tr>
<tr>
<td>Hydroxylases (known as DNA demethylases)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TET1</td>
<td>30</td>
<td>N</td>
<td>DNA</td>
<td>Y</td>
</tr>
<tr>
<td>TET2</td>
<td>30</td>
<td>N</td>
<td>DNA</td>
<td>Y</td>
</tr>
<tr>
<td>JmjC demethylases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KDM4A</td>
<td>173</td>
<td>Y</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM4A</td>
<td>57</td>
<td>N</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM4C</td>
<td>158</td>
<td>Y</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM4E</td>
<td>197</td>
<td>Y</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM5A</td>
<td>90</td>
<td>Y</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM5B</td>
<td>40</td>
<td>N</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM5C</td>
<td>35</td>
<td>N</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM5D</td>
<td>25</td>
<td>N</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM6A</td>
<td>180</td>
<td>Y</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
<tr>
<td>KDM6B</td>
<td>20</td>
<td>N</td>
<td>Histone H3</td>
<td>Y</td>
</tr>
</tbody>
</table>

* Median $K_M$ from multiple studies

[H1] **Effects of hypoxia on gene transcription**

It is now appreciated that the cellular and organism response to hypoxia involves profound changes to gene expression, with vast changes in gene transcription being detected in all systems studied.
Figure 2. Hypoxia via the regulation of 2-OGDs has the potential of controlling all aspects of gene expression and protein function. Action of JmjC-histone demethylases and TETs (mediators of DNA demethylation) will impact on chromatin and DNA regulation. RNA demethylases, and several hydroxylases acts on mRNA processing, and fate. Hydroxylases also control rates of translation and ribosome activity, while JmjC-demethylases and hydroxylases can control protein function directly or indirectly by controlling other PTMs.

Hypoxia-induced changes to transcription are largely mediated by HIF

As mentioned earlier HIFs are the master regulators of gene transcriptional changes in hypoxia. HIFs are known to bind to Hypoxia Responsive Elements (HREs) (5-(A/G)CGTG-3) of DNA [8]. Since the identification of the Erythropoietin gene (EPO) as the first hypoxia responsive HIF target gene, we now know HIF controls a wide range targets, influencing numerous biological processes,
including angiogenesis, glycolysis, cell death and cell cycle progression (reviewed in [2,10]). There are now thousands of identified hypoxia responsive genes and over 100 validated HIF target genes, with over a thousand putative targets, and all classes of RNAs can be induced by low oxygen (reviewed in [11]). The discovery of hypoxia responsive genes and HIF targets has been driven greatly by transcript profiling and genome occupancy technologies, including microarrays, RNA-seq and ChIP-seq (reviewed in [12-14]). These and analyses of publicly available transcriptional datasets [15,16] have shed light on cell type differences in hypoxia responsive genes and HIF targets on a genome wide scale, as well as identifying hypoxic signatures conserved across multiple cell types. Why different cell types have different transcriptional responses to hypoxia and HIF target genes is an important question for the field, with chromatin structure organisation thought to be a major factor in conferring specificity. Further to HIF isoform expression and activity, evidence points towards pre-established chromatin accessibility and local chromatin environment, including RNA pol II availability, pre-existing promoter enhancer interactions at HREs, and HRE DNA methylation status, as cell-type specificity determinants of hypoxia transcriptional responses (reviewed in [12-14,17]).

Whilst most HIF binding sites are at proximal promoters, binding to distal intergenic regions also occurs and HIF can regulate transcription of long genomic intervals, interacting at promoter-enhancer loops [18-20]. Although there is no doubt HIF is the main transcription factor controlling hypoxia-induced transcriptional changes, there is the involvement of other transcription factors, including Nuclear Factor-κB (NF-κB), Tumor Protein p53 (p53), MYC Proto-Oncogene (MYC) and Activator Protein 1 (AP1), which function in the regulation of the hypoxia response via HIF-dependent and independent pathways (reviewed in [21]). In addition, HIF mostly acts as an activator of transcription, and thus most of the observed hypoxia-induced gene silencing is either independent of HIF, or via indirect mechanisms, including through the actions of chromatin remodeller complexes, co-repressor complexes or induction of other transcription factors (reviewed in [22]).

**Functions encoded by HIF-induced genes**

HIF induced genes are involved in a variety of different pathways, acting at different stages of the response to hypoxia (Figure 3). For example, genes involved in restoration of oxygen homeostasis including angiogenesis and red blood cell production, involved in metabolic shift (metabolism and epigenetics), preservation of energy (cell cycle, apoptosis, autophagy, epigenetics) and adaptation to the hypoxic environment (angiogenesis, migration, epigenetics, metabolism).
Figure 3. HIF induced targets control a variety of important pathways in the cell. Direct HIF-dependent target genes have been involved in controlling restoration of oxygen homeostasis, angiogenesis, metabolism, epigenetics, survival and death pathways and cell cycle progression. Examples of such genes are included.

Although we now have access to a vast number of transcriptomic studies of cells in hypoxia, very few studies have investigated the proteomic changes under such an important stress, using techniques ranging from the “old-fashioned” two-dimensional electrophoresis (2-DE) coupled with MALDI-TOF-TOF-MS [23], Sharma, 2013 #656;Hoang, 2001 #293), to the more accurate and robust quantitative multiplexed proteomics workflow [24-27], which usually combines isobaric labelling, two-dimensional liquid chromatography (2D-LC) and high resolution MS. The few studies available have shown that hypoxia exposure of different cells and tissues possesses broad effects at the whole proteome level, including changes to the protein expression of annexin family [23], glycolytic and
antioxidant enzymes [28, 29], transcription factors [30], heat shock proteins, S100 family proteins [24], and also other proteins involved in TCA-cycle [31], metabolism [32] and immune response [25]. A proteomic study has revealed novel non-HIF hypoxia regulators, including the chromatin organizer protein Heterochromatin Protein 1 Binding Protein 3 (HP1BP3), which mediates chromatin condensation [26]. The use of multi-omics techniques (transcriptomics, proteomics and metabolomics) and analysis using integrated bioinformatics identified consistent changes to proteins and metabolites in heart tissues under antenatal hypoxia. These proteins and metabolites are involved in energy metabolism, oxidative stress and inflammation-related pathways, required for the reprogramming of the mitochondrion [27].

Analysis of secreted proteins (secretome) show hypoxic conditions usually selectively increase their expression with relevance to angiogenesis, inflammation, extracellular matrix [33] and signalling processes [34]. In prostate cancer cells adapting to hypoxia during proliferation, the secretome controls hypoxia-dependent intercellular signalling, resulting in higher protein content (primarily in epithelial adherens junction pathway) higher metalloprotease activity and increased levels of diverse signalling molecules Transforming Growth Factor Beta 2 (TGF- β2), (Tumour Necrosis Factor) (TNF), Interleukin 6 (IL6), Tumor Susceptibility 101 (TSG101), AKT Serine/Threonine Kinase 1(AKT), Integrin Linked Kinase (ILK), and Catenin Beta1 (CTNNB1) compared to exosomes at normal oxygen tensions. The results suggested that under hypoxia, with loading unique proteins in exosomes, cancer cells could enhance invasiveness and create/change the microenvironment for aggressiveness [35].

**Preferred translation of hypoxia target**

Despite hypoxia decreasing global translation due inhibition of translation initiation (please see below), cells still require translation of hypoxia-inducible genes to promote cell survival and restore oxygen homeostasis (Figure 3). This paradox is resolved through mechanisms of selective translation, for which several mechanisms have been identified. The first discovered mechanism of selective translation was internal ribosomal entry sites (IRES) [G] in the 5’ UTR which facilitates ribosome assembly within the mRNA bypassing the requirement of elF4 5’ cap initiation [36]. These sequences are present in hypoxia inducible genes such as Vascular Endothelial Growth Factors (VEGFs) [37], Fibroblast Growth Factors (FGF$s$) [38], Platelet derived Growth Factors (PDGF$s$) [39], Epidermal Growth Factor Receptor (EGFR) [40] and HIF1A [41,42]. Preferential translation of these target genes allow adaptation to low oxygen through stimulating broad programmes of gene transcription for angiogenesis, cell survival, and HIF-dependent gene changes.

Another mechanism relies on the presence of upstream open reading frames (uORFs) which are short sequences in mRNA 5’ UTRs including an upstream AUG (uAUG) start site. In normoxia when Eukaryotic Translation Initiation Factor (elF) 2A (elF2α) activity is high, translation will initiate at the first 5’ uORF, preventing translation from the genuine UAG start site. In hypoxia, when elF2α phosphorylation is high, and activity is low, the ribosome will identify the uAUG flanking sequence to bypass the uORF site, so translation mostly shifts to the downstream genuine ORF, resulting in an increase in translation of the gene [43] This mechanism has been identified for the EPO gene in response to hypoxia [43].

Some mRNAs contain an RNA HRE (rHRE), a sequence which can recruit an alternative initiation complex for selective cap-dependent translation [44]. This complex involves HIF-2α, one of
the HIF family of transcription factors stabilised in hypoxia through PHD inhibition, RNA Binding Motif Protein 4 RBM4, and the eIF4E homologue eIF4E2, which together in hypoxia bind to rHREs and initiate translation of genes such as EGFR, PDGR Receptor Alpha (PDGFRα), and Insulin Like Growth Factor 1 Receptor (IGF1R). Finally, a potentially new and exciting mechanism involves an epigenetic transcriptomic mark in RNA, methylation of 6 adenosine (m6A). mRNA m6A modification at the 5'UTR can recruit m6A binding proteins such as YTH N6-Methyladenosine RNA Binding Protein 2 (YTHDF2) in heat shock stress which upregulates translation through binding eIF3 and the 40S subunit [45], and such a mechanism may prove true in other stress responses such a hypoxia. The RNA demethylating enzymes FTO Alpha-Ketoglutarate Dependent Dioxygenase (FTO) and AlkB Homolog 5, RNA Demethylase (ALKBH5), are 2-OGDs, and although their ability to sense oxygen has yet to be investigated, their inhibition in hypoxia could result in an increase in global RNA methylation, which would help to regulate translation and RNA fate in hypoxia.

**Chromatin regulation in hypoxia**

Central to the hypoxia response is the activation of a dynamic transcriptional programme. HIF transcription factors are the primary mediators of hypoxia induced gene transcriptional changes (reviewed in [8]). Further to HIF stabilisation and activation under low oxygen tensions, the chromatin landscape also plays a complex role in co-ordinating hypoxia inducible changes to gene transcription. Most aspects of chromatin regulation are altered in response to low oxygen, including histone methylation and acetylation, DNA methylation, actions of chromatin remodeller complexes and non-coding RNAs, histone eviction and incorporation of histone variants, and chromatin accessibility (reviewed in [11-13]). However, this is still a vastly unexplored aspect of the hypoxia response. As mentioned above, in addition to PHDs, TETs (mediators of DNA demethylation), and JmjC demethylases (histone and non-histone protein demethylases), are also 2-OGDs. Recent studies demonstrate the potential of TETs and JmjC demethylases to function as molecular oxygen sensors, directly linking oxygen sensing to transcriptional control via epigenetics in cells. Below we summarise DNA and histones methylation changes in hypoxia, with a focus on oxygen sensing mechanisms via TETs and JmjC demethylases. (Figure 4).
Figure 4. Chromatin oxygen sensing via JmjC histone demethylases and TETs. JmjC histone demethylases and TETs (mediators DNA demethylation) are 2-OGDs. Reduced activity of these enzymes in hypoxia, due to their oxygen sensitivity, can alter the chromatin landscape and mediate hypoxia induced transcription changes. Reduced activity of KDM5A in hypoxia increases H3K4me3 at the promoters of a subset hypoxia induced genes, facilitating their transcriptional activation. Reduced
activity of KDM6A in hypoxia increases H3K27me3 at the promoters of a subset of hypoxia-repressed genes and represses their transcription. Reduced TET1/2 activity in hypoxia also represses gene transcription via DNA hypermethylation at gene promoters.

**JmjC histone demethylases and chromatin regulation in hypoxia**

Histone methylation is a recognised mechanism controlling chromatin structure and is associated with regulation of gene transcription, with some marks clearly leading to open chromatin, while other are firmly associated with closed conformation [46]. The family of enzymes predominantly responsible for histone demethylation are JmjC demethylases, which are part of the JmjC-domain containing group of 2-OGDs which includes demethylases and hydroxylases (JmjC 2-OGDs). *In vitro* studies demonstrate the varied oxygen sensitivities of these enzymes, some are potentially direct molecular oxygen sensors (Box 1). Oxygen affinities, oxygen availability and protein expression levels will likely dictate JmjC demethylase activities in hypoxia. Several groups have reported increases in total levels of histone methylation modifications in response to hypoxia across a range of human and mouse cell types and human tumours using immunoblotting, immunohistochemistry, immunofluorescence and quantitative proteomics ([47], reviewed in [12]). ChIP-sequencing approaches have revealed site-specific, hypoxia induced changes in Histone (H)3 Lysine (K)4 trimethylation (me3) [10,48], H3K36me3 [10] and H3K27me3 [48,49], which correlate with changes in gene expression. There is now evidence, through the use of *in vitro* and in cell histone demethylation assays, in coordination with mutagenesis analysis, gene expression analysis and histone methylation analysis, that Lysine Demethylase (KDM) 6A (KDM6A) [49] and potentially KDM5A[10], which demethylate H3K27me3 and H3K4me3 respectively, are inhibited by reduced oxygen levels in hypoxia. These result in increased histone methylation modifications which coordinate hypoxia inducible gene transcriptional changes (Figure 4) and hypoxia induced cellular responses. Specifically, KDM6A inhibition in hypoxia triggers hypermethylation of H3K27me3 at a subset of hypoxia repressed gene promoters, reducing their expression. Conversely, potential KDM5A inhibition in hypoxia, triggers H3K4me3 hypermethylation at a subset of hypoxia inducible gene promoters, this precedes increases in their expression in hypoxia and is required for their full transcriptional activation in hypoxia. In cell and *in vitro* H3K9me3 demethylation assays have also revealed that the demethylase activity of KDM4A is highly sensitive to oxygen concentrations over physiologically relevant ranges, thus KDM4A can also be classed as an oxygen sensor [50]. Interestingly, KDM4A has been shown to positively regulate HIF-1α levels via H3K9me3 demethylation at the HIF1A gene locus, this effect is observed in mild hypoxia (2% oxygen), but impaired at severe hypoxia (>0.1 oxygen) [51]. This may provide a mechanism of increasing HIF-1α levels in conditions of hypoxia, were this is still residual PHD activity. Future work should investigate if the oxygen sensitive H3K9me3 demethylase activity of KDM4A is linked to control of gene expression and chromatin regulation in hypoxia. Importantly, some JmjC demethylases remain active at low oxygen concentrations and function in hypoxia through histone their demethylase activity. KDM4C [52] and KDM3A [53,54]display HIF coactivator activity in hypoxia via demethylation of H3K9 at HIF target gene promoters, facilitating transcriptional activation at the genes. Furthermore, many JmjC histone demethylases are HIF target genes that are upregulated in hypoxia (reviewed in [55]), this is thought in part to be a compensatory mechanism to counteract reduced demethylase activity acting as a hypoxia feedback loop similar to what is seen with
transcriptional upregulation of PHD2/3 by HIF. Thus, there is complex crosstalk between histone methylation, gene expression and hypoxia, mediated in part through JmjC demethylases. However, further characterisation of the oxygen sensitivities of JmjC demethylases is needed.

**TET mediated DNA demethylation functions in hypoxia**

TETs, of which there are 3 variants, Ten Eleven Ten translocation Methylcytosine Dioxygenase 1 (TET1), TET2 and TET3, are 2-ODGs which function as hydroxylases, mediating mammalian DNA demethylation through catalysing the oxidation of 5methylcytosine (5mc) to 5-hydroxymethylcytosine, 5-formylcytosine and 5-carboxylcytosine. These TET oxidised derivatives of 5mc can then be demethylated by mechanisms of active and passive demethylation (reviewed in [56]). DNA methylation can repress gene transcription, consequently tumour hypoxia results in aberrant DNA methylation profiles promoting tumour suppressor gene silencing (hypermethylation) [57] and oncogene activation (hypomethylation) [58]. Recently, using *in vitro* biochemical binding assays, *in vivo* studies on HIF binding and DNA methylation status in human cancer cell lines, and in silico structural modelling D’Anna and colleagues find that DNA methylation at HREs impairs HIF binding, and HRE DNA methylation status is a key factor in determining cell type specific transcriptional responses to hypoxia[59]. There is heterogeneity regarding the effects of hypoxia, both in cell models and in tumours, on global DNA methylation levels and TET activity (reviewed in [11,60]). As such, whether TETs are impaired or functionally active in hypoxia, and the consequences this has for gene transcription appear highly context dependent. Researchers have shown TET activity in hypoxia, and HIF dependent TET upregulation and coactivator functions, have been demonstrated at hypoxia inducible genes (reviewed in [11,60]). TET activity in low oxygen environments is supported by *in vitro* oxygen affinities of TET1 and TET2 (Box 1) and is supported by the known roles of TETs in the bone marrow and during development where oxygen tensions are low [61,62]. Conversely, Thienpont et al. showed that severe hypoxia (0.5% oxygen) in human and murine cells and tumour hypoxia in multiple human tumours causes DNA hypermethylation at gene promoters correlating with gene silencing at a subset of hypoxia repressed genes and gene silencing linked to hypoxia associated tumour progression. DNA hypermethylation was attributed to oxygen dependent reduction in TET1 and TET2 activity in hypoxia, with a 50% reduction in activity observed at 0.3% oxygen for TET1 and 0.5% for TET2 *in vitro*. Thus, TET1 and TET2 may be characterised as tumour oxygen sensors, and depending on the context of oxygen deprivation, may remain active in hypoxia environments or display inhibition. However, more work is needed to establish the oxygen dependence of TET activity in cells and *in vivo* and the physiological contexts in which TETs can sense changes in oxygen availability as well as the consequences this has for DNA methylation, gene transcription and cellular responses. Indeed, the seemingly contradictory roles for TETs in hypoxia from studies to date may be dependent on the different cell models used and timing/severity of hypoxic stimulus.

While there is growing evidence for a dynamic role of chromatin/epigenetics in sensing and responding to hypoxia to facilitate transcriptional changes, via dependent and independent HIF mechanisms, efforts to elucidate molecular mechanisms underpinning such changes and the extent to which chromatin/epigenetic changes are required for coordinating hypoxia/HIF transcriptional effects are ongoing. The discoveries of oxygen sensing by TETs and JmjCs provide an exciting link
between oxygen availability and chromatin regulation and future work on oxygen sensing by chromatin will be essential in better hypoxia driven processes.

**Effects of hypoxia on protein levels**

Protein levels and function are key aspects to achieve the correct hypoxia response. Although transcription is important, mechanisms controlling protein levels and function supersede any change in transcriptional output. In hypoxia, mechanisms exist that control translation but also post-translation aspects of protein function.

*Translation is globally repressed in response to hypoxia*

In addition to the regulation of gene transcription in hypoxia, gene expression is also controlled through regulation of translation (Figure 5). The cellular response to hypoxia includes a reduction in the energy demands of the cell due to limited ATP production through oxidative phosphorylation. This adaptation results in a reversible global decrease in energy-expensive protein synthesis (reviewed in [2]). This inhibition of translation is a highly regulated response to low oxygen levels preceding ATP depletion (reviewed in [2]).
Figure 5. Hypoxia induces a global inhibition of protein translation. Global translation is mostly inhibited at initiation through mTOR inhibition of eIF4 and PERK inhibition of eIF2α, which then inhibit cap-dependent translation of mRNA. mTOR is inhibited through hypoxia-induced DDIT4-dependent release of TSC2 from 14-3-3 binding proteins resulting in the TSC1/2 dimer inhibiting mTOR. Elongation is also regulated through mTOR, as well as AMPK through its inhibition of RPS6KB1, for in hypoxia eEF2K is not inhibited, which allows its phosphorylation and inhibition of eEF2. PHD2 can also hydroxylate eEF2K, which in normoxia causes its disassociation from calmodulin, decreasing its autophosphorylation. Termination is regulated by JMJD4-mediated hydroxylation of eRF1 which is required for termination. Selective translation of genes in hypoxia is regulated by UTR sequences such as IRES and uORFs, which allow increased translation specifically in hypoxia. RNA binding proteins can bind to various parts of the mRNA and result in different regulatory outcomes. Hydroxylation of splicing regulatory (SR) proteins results in differential splicing or exon choice, such as skipping the
first exon with the hydroxylation of SRSF11. The ribosome can also be hydroxylated by RIOX1 and RIOX2, though it is not yet clear what role these modifications have.

Global inhibition of protein expression is largely regulated at the point of translation initiation through two pathways. Firstly, Mechanistic Target Of Rapamycin Kinase (mTOR) is inhibited by DNA Damage Inducible Transcript 4 (DDIT4) (a HIF target gene). DDIT4-dependent release of TSC Complex Subunit 2 (TSC2) from 14-3-3 binding proteins leads to mTOR inhibition. This allows the formation of an active TSC1-TSC2 dimer inhibiting the phosphorylation of Ribosomal Protein S6 Kinase B1 (RPS6KB1) by the protein complex, mTOR, which in turn inhibits the phosphorylation of Ribosomal Protein S6 (RPS6), part of the 40S ribosomal subunit required for initiation [63]. mTOR inhibition also causes hypophosphorylation of Eukaryotic Translation Initiation Factor (eIF) 4E Binding Protein 1 (eIF4EBP1) allowing sequestering of eIF4E, decreasing 5’cap-dependent initiation [64,65]. Secondly, PKR-like Endoplasmic Reticulum Kinase (PERK) (gene name EIF2AK3) is phosphorylated and activated, subsequently phosphorylating eIF2α at S51 causing effective inactivation [66]. Phospho-eIF2α prevents binding with eIF2B for exchange of GDP for GTP, therefore remaining in an inactive state and preventing subsequent rounds of translation from the mRNA [67]. eIF2α normally recruits the initiator aminoacylated tRNA to the 40S ribosome, thus limiting global initiation of translation. This second mechanism is independent of HIF and as of yet has not been linked to any 2-OGD.

Inhibition of translation is also regulated at the stage of polypeptide elongation. Elongation is inhibited by phosphorylation of Eukaryotic Elongation Factor 2 (eEF2) at T56 by eEF2 Kinase (eEF2K) [68]. This process has been shown to be dependent on mTOR and 5’-AMP-activated protein kinase catalytic subunit alpha-1 (AMPK) (gene name PRKAA1)[69,70] Interestingly, eEF2 kinase (eEF2K) is also regulated by hydroxylation by PHD2 at P98 in an oxygen-dependent manner [71]. In hypoxia, when PHD2 inhibited, eEF2K activity is induced.

In addition to PHD2 dependent hydroxylation, there are several other hydroxylation reactions involved in the regulation of translation, catalysed by other 2-OGDs. Hydroxylation is important for the biosynthesis of tRNAPhe with position 37 requiring a hypermodified nucleoside Wybutosine (yW), which can be hydroxylated to form hydroxywybutosine (OHyW), by the JmjC hydroxylase, TRNA-YW Synthesizing Protein 5 (TYW5), which maintains translational fidelity. It is currently unknown whether TYW5 is responsive to the levels of oxygen, but its transcription is decreased in hypoxia [72] linking hypoxia to a decreased accuracy of translation, which globally decreases the successful translation of proteins [73].

The rate and accuracy of translation are positively regulated by hydroxylation of the central translation machinery. JmjC hydroxylases hydroxylate histidyl residues in ribosomal proteins, with Ribosomal Oxygenase 2 (RIOX2) 2 and RIOX1 hydroxylating Ribosomal Protein L (RPL) 27a (RPL27A) and (RPL8), respectively. The hydroxylation occurs at residues close to the peptidyl transfer centre, thereby increasing translation efficiency [74]. RIOX1 and RIOX2 transcription is reduced in hypoxia [72,74]. Furthermore, RPL8 hydroxylation is also reduced in hypoxia [74]. However, it is not yet known whether these enzymes are inhibited by low oxygen levels, or lower hydroxylation is solely due to lower transcription. Additionally, hydroxylation of 40S Ribosomal Protein S23 (RPS23) by the 2-OGD, 2-Oxoglutarate And Iron Dependent Oxygenase Domain Containing 1 (OGFOD1), is required for efficient translation [75]. OGFOD1 transcription is also decreased in hypoxia, but the enzyme remains
mostly active even in acute hypoxia [76], suggesting this mechanism is not through direct 2-OGD oxygen sensing. Efficient decoding of the mRNA during translation requires the JmjC hydroxylase, AlkB Homolog 8, TRNA Methyltransferase, ALKBH8, which hydroxylates tRNA at the wobble position [77,78]. This 2-OGD has yet to be linked to hypoxia, though it would be interesting to investigate its oxygen sensitivity. Finally, lysyl hydroxylation of eukaryotic release factor 1 (eRF1) by the JmjC hydroxylase Jumonji Domain Containing 4 (JMJD4) is required for proper termination of translation [79], although its activity is not significantly inhibited in hypoxia.

**Utilising proteomics for the identification of non-histone protein PTMs**

Proteomics approaches revealed hypoxia induces changes to many post translational modifications (PTMs) on non-histone proteins, such as proline hydroxylation[80,81](regulating protein levels and interactions), phosphorylation [82,83], SUMOylation [84], acetylation[85], glycosylation[86], nitration[87] and nitrosylation[88](all of which regulate protein functions in different ways).

As one of the most widely studied PTMs, the phosphorylation on some transcriptional factors and regulators has been found to be changed under various hypoxic conditions, CAMP Responsive Element Binding Protein 1CREB1, NFKB Inhibitor Alpha (NFKBIA), a regulator of NF-κB, and HIF (reviewed in [89]). More recently, through the analysis of phospho-proteomics in renal clear cell carcinoma cells under VHL-independent hypoxic responses, up-regulation of known biomarkers of RCC and signalling adaptor were found. Meanwhile, such hypoxic responses decreased the phosphorylation on intracellular Carbonic Anhydrase 2 (CA2), which might be an unusual way to control the CA2 expression and enhance the activity of the NFκB pathway, resulting in loss of VHL [82].

In recent years, non-HIF targets have been identified to be hydroxylated on prolines by PHDs (reviewed in [13]), resulting in their degradation and/or changes to downstream activity including Centrosomal Protein 192 (CEP192)[90] and Forkhead Box O3 (FOXO3)[91] by PHD1, Actin Beta (ACTB) by PHD3[92], and AKT Serine/Threonine Kinase 1 (AKT1) by PHD2[93]. Interestingly, a new study indicated that prolyl-hydroxylation could be crucial for GMGC kinase activation [94]. This could imply an intricate interplay between these two types of PTMs, suggesting yet another role for oxygen-dependent signalling in the cell.

Other common PTMs have also been found to responding hypoxia in their own ways. The deSUMOylation of Transcription Factor AP-2 Alpha (TFAP2A), which is known to interact with HIF-1, could enhance the transcriptional activity of HIF-1 under hypoxic conditions [84]. Hypoxia could increase the NAD+-sensitive Siruin 3 (SIRT3) activity, that deacetylates key metabolic enzymes and significantly changes the acetylation pattern within the mitochondria. This results in reduced mitochondrial oxidative capacity to match the lowered oxygen availability [85]. In cancer cells, HIF-1α and Glucose transporter 1 (GLUT1) (gene name SLCA1) are critical for O-linked GlcNAc Transferase-mediated regulation of metabolic stress. Reducing O-GlcNAcylation levels increases alpha-ketoglutarate, HIF-1α hydroxylation, and interaction with VHL, resulting in HIF-1α degradation [95]. Some glycosylation also takes part in driving the cell migration and invasion under hypoxia (Reviewed in [86]).
Thus, unbiased proteomic studies on novel PTMs sites [80,96], system-wide analysis of PHDs substrates other than HIF-α [81] and crosstalk of PTMs on PHDs targets in response to hypoxia are now emerging.

**Other potential roles of JmjC 2-OGDs in the hypoxia response**

Further to known and potential oxygen sensing roles of JmjC 2-ODGs (demethylases and hydroxylases) in regulation of chromatin and translation discussed earlier, there are other functions of JmjC 2-ODGs which may influence the hypoxia response (Figure 6). One of the most prominent such enzymes is the dual function of the JmjC 2-OGD, JMJD6, Arginine Demethylase And Lysine Hydroxylase, which has unique activity as both an arginine demethylase and lysine hydroxylase [97,98]. JMJD6 expression is increased in hypoxic conditions in the placenta, and can downregulate HIF-1α [99], though it has been found to operate in diverse pathways. JMJD6 can promote the formation of stress granules through demethylation and de-repression of G3BP Stress Granule Assembly Factor 1 G3BP1, resulting in the cytoplasmic sequestering of stalled mRNA-ribosome complexes to reversibly prevent mRNA degradation [100,101]. This would allow a fast re-start of protein synthesis when oxygen homeostasis is restored. JMJD6 also regulates mRNA splicing through hydroxylating the splicing regulatory (SR) proteins LUC7 Like 2, Pre-MRNA Splicing Factor (LUC7L2, U2 Small Nuclear RNA Auxiliary Factor 2 (U2AF2) [102], and Serine And Arginine Rich Splicing Factor 11 (SRSF11) [98]. The SR proteins are involved in exon definition and alternative splicing, with SRSF11 hydroxylation resulting in skipping of the most 5' exon, and hydroxylation of U2AF65 possibly enacting pre-mRNA looping in order to present to the splicing machinery different cis splice enhancer or silencer sequences [103]. However, this only occurs for selected mRNAs and is not a global effect [103]. Nevertheless, this mechanism would allow selection of alternate splice variants as a response to hypoxia. JMJD6 can also interact with both Bromodomain Containing 4 (BRD4) and the positive Transcription Factor Elongation Factor b (P-TEFb) complex [104], eventually resulting in the release of paused DNA polymerase II and resumption of mRNA synthesis at specifically regulated genes [103]. This implies that hypoxia could use this mechanism to stall transcription of genes that are not required for the stress response to hypoxia and would allow a re-start of gene expression when oxygen levels are restored.

Another JmjC hydroxylase, KMD8, which can hydroxylate arginine residues in both RCC1 Domain Containing 1 (RCCD1) and RPS6 [105]. Although not necessarily dependent on its hydroxylation activity, KDM8 is required for cell proliferation and chromosomal stability [106], and can negatively regulate p53 affecting gene expression and control cell cycle and proliferation [107,108]. Also recently, a biochemical function has been assigned to JMJD7 as a lysyl hydroxylase, which targets Developmentally Regulated GTP Binding Protein 1 (DRG1) and DRG2, which are part of the Translation Factor (TRAFAC) family of GTPases, and could affect their binding with messenger, or ribosomal RNA, though this requires further investigation [109].

The JmjC demethylase, KDM2A represses NF-κB activity via demethylation of RELA, providing a possible link to hypoxia and inflammation crosstalk. [110]. It is more than likely that other JmjC demethylases interact and directly demethylate additional transcription factors which may coordinate transcriptional responses to hypoxia. However, unbiased analysis is required to fully assess this aspect of hypoxia induced gene regulation.
Relevance to human biology and health

Although we currently do not know the importance of all of the 2-OGDs present in the genome, several of the key players in the hypoxia response have important functions and relevance to human biology and health. This is exemplified by the phenotypes observed in null mice, or by the presence of disease associated mutations in humans.

**Figure 6.** Other potential roles of JmjC 2-OGDs dioxygenases in the hypoxia response. JmjC-demethylases have additional functions in the cell, involving control RNA splicing, transcription elongation, translation and RNA fate.

**PHD/HIF/VHL axis**

Given the cellular functions mentioned above, it is no surprise that genetic mutations of most dioxygenases and HIFs have been implicated with human diseases. Mutations in *HIF-2α* and *PHD2* have been found in patients with vascular pathologies, such as erythrocytosis, polycythemia, and
pheochromocytoma (Table 1). As HIF mediates hypoxia adaptation responses, including the regulation of erythropoiesis and vasculogenesis, it is not surprising that mutations within the PHD/HIF/VHL axis are associated with vascular pathologies. The crucial role of HIFs in vascular pathologies is strongly demonstrated by genetic studies of mice, as highlighted in Supplementary Table 1. Knockout mice of HIF-1α or HIF-2α are embryonic lethal with vascular defects (Table 1, Supplementary Table 1), whereas the deletion of PHD2 that activates HIF signalling results in embryonic lethality in mice due to placental and heart defects (Table 1, Supplementary Table 1). VHL mutations also result in highly vascularized tumours, including pheochromocytomas, renal cell cancer carcinoma, retinal and central nervous system hemangioblastomas (Table 1). Hundreds of VHL mutations have been identified in VHL syndrome patients (listed in the Human Gene Mutation Database [111]). The homozygous VHL mutation R200W, which prevents efficient HIF-α degradation in normoxia, is found in all individuals with Chuvash Polycythemia (CP) [112]. CP is characterized by congenital erythrocytosis, and patients have been associated with pulmonary hypertension, thrombosis, vertebral hemangiomas, cerebral vascular events and other vascular abnormalities [113,114], displaying the role of VHL in HIF-dependent regulation of vasculogenesis and erythropoiesis.

Table 1 | Available mice and human mutations phenotypes for HIF and dioxygenases.

<table>
<thead>
<tr>
<th>Gene (mouse/human)</th>
<th>Homozygote phenotype in mouse</th>
<th>Human phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIFs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hif1a/HIF1A (HIF-1α)</td>
<td>Embryonic lethal with cardiovascular malformations, cephalic vascularisation and neural tube defects [115-117]*.</td>
<td>Schizophrenia [118]<em>. Maximal oxygen consumption [119]</em>. Renal cell carcinoma [120]*.</td>
</tr>
<tr>
<td>Epas1/EPAS1 (HIF-2α)</td>
<td>Embryonic lethal with bradycardia due to defective catecholamine homeostasis [121]<em>, vascular remodelling defects [122]</em>, cardiac failure and neonatal lethal with respiratory failure [123].</td>
<td>Congenital heart disorder [124]<em>. Autism spectrum disorder [125]</em>. Pheochromocytoma/parangangiola-polycthaemia [126,127] [128-130] [131] [132]<em>/somatostatinoma [133]</em>. Erythrocytosis and polycythaemia with paraganglioma [128-130]<em>. Erythrocytosis [134-139]</em>. Pulmonary arterial hypertension [140]*.</td>
</tr>
<tr>
<td>Hif3a/HIF3A (HIF-3α)</td>
<td>Mice deficient of an alternative spliced protein of HIF-3α, NEPAS, are viable and develop enlarged right ventricular owing to</td>
<td>NR</td>
</tr>
<tr>
<td>2-OGDs- hydroxylases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td><strong>Egln2/EGLN2 (PHD1)</strong></td>
<td>Viable [142]*.</td>
<td>Increased risk of hepatocellular carcinoma [143]<em>, lung cancer [144,145]</em>, gastric cancer [146]<em>, colorectal cancer [147]</em>. Pheochromocytoma/paraganglioma-polycythemia [148]*.</td>
</tr>
<tr>
<td><strong>Egln1/EGLN1 (PHD2)</strong></td>
<td>Embryonic lethal with severe cardiac and placental defects [142]*.</td>
<td>High-altitude adaptation [133]<em>. Erythrocytosis [149,150]</em>,[151]<em>,[152]</em>,[153]<em>,[154]</em>,[155]<em>,[156]</em>,[149,157]<em>,[158]</em>,[159]<em>. Pheochromocytoma/paraganglioma-polycythemia [148]</em>. Pheochromocytoma [127]<em>. Cardiopulmonary [160]</em>.</td>
</tr>
<tr>
<td><strong>Egln3/EGLN3 (PHD3)</strong></td>
<td>Viable [142]* with developmental defect of sympathoadrenal system [161]*.</td>
<td>NR</td>
</tr>
<tr>
<td><strong>P4ha1/P4HA1</strong></td>
<td>Embryonic lethal with delayed development and defective collagen IV assembly, resulting in base membrane rupture [162]*.</td>
<td>Congenital-onset disorder of connective tissue [163]*.</td>
</tr>
<tr>
<td><strong>P4ha2/P4HA2</strong></td>
<td>Viable and fertile with no obvious phenotypic abnormalities [164]*.</td>
<td>High myopia [165]*.</td>
</tr>
<tr>
<td><strong>Phyh/PHYH (PAHX)</strong></td>
<td>Viable without distinct developmental abnormalities [166]*.</td>
<td>Refsum disease [167]<em>,[168]</em>,[169]<em>,[168]</em>,[170]<em>,[171]</em>,[172]<em>,[173]</em>. Nonsyndromic cleft lip and palate [174]*.</td>
</tr>
<tr>
<td><strong>Hif1an/HIF1AN (FIH)</strong></td>
<td>Abnormal energy metabolism with reduced body weight, elevated metabolic rate and hyperventilation [175]*.</td>
<td>Colorectal cancer [176]*.</td>
</tr>
<tr>
<td>2-OGDs - hydroxylases (mediators of DNA demethylation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tet1/TET1</strong></td>
<td>Knockout of TET1 via 5' coding sequence results in partial embryonic lethal in mice [177-179]<em>, with surviving female mice displaying decreased fertility and reduced ovary size due to meiotic abnormality [177,178]</em>. Whereas,</td>
<td>NR</td>
</tr>
</tbody>
</table>
mice knockout via deletion of the catalytic domain of *TET1* are viable and fertile [179-181]*, with slightly reduced body size [180]*, as well as impaired spatial learning and short-term memory [182]*.

<table>
<thead>
<tr>
<th>Tet2/TET2</th>
<th>Disordered hematopoiesis and eventually develop myeloid malignancies [183-185], and T- and B-cell malignancies [184]*.</th>
<th>Myelodysplastic/myeloproliferative disease [186]<em>. Prostate cancer [187]</em>. Myeloproliferative neoplasms [188]*.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tet3/TET3</td>
<td>Neonatal lethality [178,189]*.</td>
<td>Intellectual disability, developmental delay, autistic traits, hypotonia, growth abnormalities, facial dysmorphism and movement disorders [190]*.</td>
</tr>
</tbody>
</table>

2-OGDs – hydroxylases (RNA demethylases)


2-ODGs – JmjC demethylases and hydroxylases

<table>
<thead>
<tr>
<th>JmjC/JMJD4</th>
<th>Viable and fertile with normal physiology [192]*.</th>
<th>NR</th>
</tr>
</thead>
<tbody>
<tr>
<td>JmjC/JMJD6</td>
<td>Perinatal lethal with growth retardation and exhibit severe tissue and organ differentiation defects, including brain, lung, liver, kidney, intestine, heart and thymus development at different stages of</td>
<td>NR</td>
</tr>
<tr>
<td>Kdm2a/KDM2A</td>
<td>Embryonic lethal with severe growth retardation and defective neural tube closure [197]*.</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Kdm2b/KDM2B</td>
<td><em>KDM2B-1-deletion mice display moderate penetrance of neural tube defects, leading to exencephaly and death at birth [198]. Whereas, mice deficient of both KDM2B-1 and KDM2B-2 isoforms are embryonic lethal with full penetrant developmental defects, including abnormal somitogenesis, reduced size, defective neural tube and heart [199-201]</em>; especially a more severe developmental in female embryos [200]<em>. Furthermore, KDM2B-2-deleted mice also display similar developmental abnormalities and increased lethality, particularly in females [200]</em>.</td>
<td></td>
</tr>
<tr>
<td>Kdm3a/KDM3A</td>
<td>Develop obesity, abnormal fat metabolism [202,203]<em>, reduced energy expenditure, and display metabolic syndrome, including, high plasma cholesterol, insulin, triglyceride, and leptin levels [203]</em>. Male infertility [206]*.</td>
<td></td>
</tr>
<tr>
<td>Kdm3b/KDM3B</td>
<td>Postnatal growth restriction and female mice were infertile due to decreased ovulation, prolonged estrous cycles, reduced fertilisation and uterine decidual response [207]<em>. Male knockout mice have impaired reproductive function, sperm development and maturation [207]. Knockout mice exhibit myelodysplastic syndrome and defective hematopoiesis including leukocytosis, moderate anemia, and granulocytosis [208]</em>.</td>
<td>Schizophrenia [209]<em>. Intellectual disability [210]</em>. Wilms tumour and hyperpigmentation [211]<em>. Hepatoblastoma, autism, intellectual disability, and abnormal pigmentation [211]</em>. Acute myeloid leukemia, mild intellectual disability, congenital hypothyroidism and congenital hip dysplasia [211]<em>. Hodgkin lymphoma, feeding difficulties, intellectual disability, umbilical and inguinal hernia [212]</em>. Intellectual disability, facial dysmorphism and short stature [212]*.</td>
</tr>
<tr>
<td>Jmd1c/JMJD1C</td>
<td>Males gradually develop infertility with decreasing testes size due to progressive loss of germ cells [208]*.</td>
<td>Congenital heart disease in patients with 22q11.2 deletion syndrome [213]<em>. Rett syndrome [214]</em>[215]<em>. Autism spectrum disorder [214]</em>. Intellectual disability [214]<em>. Intracranial germ cell tumour [146]</em>.</td>
</tr>
<tr>
<td>Kdm4a/KDM4A</td>
<td>Viable [216]*.</td>
<td>NR</td>
</tr>
<tr>
<td>Kdm4b/KDM4B</td>
<td>Viable [217]<em>. Viable with lower birth rate. Early weaning results in death. Susceptible to obesity with impaired energy expenditure, adaptive thermogenesis and adipose tissue lipolysis [218]</em>.</td>
<td>NR</td>
</tr>
<tr>
<td>Kdm4c/KDM4C</td>
<td>Viable and fertile [219]<em>. However, another reported that it leads to embryonic lethally [220]</em>.</td>
<td>Upper aerodigestive tract cancer [221]<em>. Age at menarche [222]</em>.</td>
</tr>
<tr>
<td>Kdm4d/KDM4B</td>
<td>Viable and fertile without gross abnormalities [223]*.</td>
<td>NR</td>
</tr>
<tr>
<td>Kdm5b/KDM5B</td>
<td>Embryonic lethal [227,228]<em>. Neonatal lethal due to failure to establish respiratory function, defective neural system and homeotic skeletal transformations [229]</em>.</td>
<td>Intellectual disability, dyslexia, global developmental delay, facial dysmorphism, aggressive behaviour, hypospadias [230]*.</td>
</tr>
<tr>
<td>Kdm5c/KDM5C</td>
<td>Hemizygous KDM5C null male mice are embryonic lethal due to defective neurulation and cardiogenesis [231]<em>. Male hemizygous knockout mice (Kdm5c−/y) Viable with adaptive and cognitive abnormalities, including increased aggression, impaired social behaviour, limited learning, fear memory deficits, defective dendritic spines [232,233]</em> and significant reduced body weight [233]*.</td>
<td>X-linked intellectual disability [234]<em>[235]</em>[236]<em>[237]</em>[238]<em>[239]</em>[240]<em>[241]</em>[242] [243]<em>[244]</em>[245]<em>[246]</em>. Autism spectrum disorder [247]*.</td>
</tr>
<tr>
<td>Kdm5d/KDM5D</td>
<td>A large scale screening using CRISPR/Cas9-mediated genome</td>
<td>NR</td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Kdm6a/KDM6A</td>
<td>Embryonic lethal with cardiac development defects and neural tube closure. While female knockout mice died mid-gestational, some hemizygous KDM6A-null male mice survive into adulthood [231,249-252] and are fertile [251,252], with reduced lifespan and smaller in size [251]. Female embryonic lethal, abnormal/truncated posterior bodies, anaemic (hematopoiesis), severe heart development defect and neural tube closure. Male died around birth due to neuron tube closure defect and inability to breath [253].</td>
<td></td>
</tr>
<tr>
<td>Kdm6b/KDM6B</td>
<td>Embryonic [266] and perinatal lethal with respiratory failure [267-269], detail reviewed here [270]. Reduced proliferation and hypertrophy of chondrocytes, as well as delayed endochondral ossification in mice [271]. Delayed osteoblast</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intellectual disability [226]. Intellectual disability, brachydactyly and dysmorphism [273].</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Phenotype Description</td>
<td>Reference(s)</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>$Uty/UTY$</td>
<td>Hemizygous male mice are viable</td>
<td>[249]*</td>
</tr>
<tr>
<td>Kdm7a/KDM7A</td>
<td>A large-scale genome-wide tissue phenotype screen revealed that abnormal hair follicles, sebaceous gland, tail and hair follicle bulge morphology in KDM7A knockout mice</td>
<td>[274]*</td>
</tr>
<tr>
<td>Phf8/PHF8</td>
<td>Impaired learning and memory, hippocampal long-term potentiation</td>
<td>[275]*</td>
</tr>
<tr>
<td>Kdm8/KDM8</td>
<td>Embryonic lethal with delayed development in multiple organs and growth retardation</td>
<td>[281]*</td>
</tr>
</tbody>
</table>

**2-OGDs - hydroxylases**

Similar to PHDs, prolyl-4-hydroxylases P4HA1 and P4HA2 are hypoxia-inducible, but P4HA1/2 prolyl hydroxylation is required for different processes, that is collagen fiber formation. Consistent to their roles in collagen synthesis, P4HA1 and P4HA2 mutations are found in patients with collagen-related extracellular matrix disorders (Table 1; Supplementary Table 1). Furthermore, homozygous deletion of P4HA1 is embryonic lethal with base membrane rupture due to defective collagen IV assembly (Table 1). PAHX is another hydroxylase, but of phytanoyl-CoA; essential for breaking down phytic fatty acid. Mutations in PAHX is well associated with Refsum disease, a rare inherited neurological disorder caused by neurotoxic phytanic acid as these mutations result in an enzymatically inactive protein, thus leading to phytanic acid accumulation.

The roles of TET1–3 in development are demonstrated in knockout mouse models (reviewed in [283]). TET1-null mice present several defects but these depend on the mode of genetic deletion. TET3 deletion results in neonatal lethality, highlighting TET3 role in development. TET3 mutations have been found in patients with intellectual disability and/or delayed global development (Table 1; Supplementary Table 1). Although somatic alterations of TET2 have been found in several cancers, these mutations are majorly associated with myelodysplastic syndromes (Table 1; Supplementary Table 1). In addition to the listed mutations in Supplementary Table 1, a study reported TET2'somatic mutations in 46 patients with myelodysplastic syndromes, myeloproliferative disorder, secondary
acute myeloid leukemia, or chronic myelomonocytic leukemia [284]. Most of these mutations are predicted to lead to partial or total loss of function due to protein truncation.

**2-OGDs - JmjC demethylases**

Many of the JmjC- demethylase genes have been associated with human diseases. In particular, several of them are mutated in patients with neurodevelopmental disorders, midline defects and cancers (Table 1; Supplementary Table 1). Although *KDM3A* is found to be mutated in infertile males [206], its role in infertility is not clear. Mutations in *KDM3B* are frequently implicated with intellectual disability, but also found in cancers including myeloid leukemias (Table 1). Similarly, *JMJD1C* mutations have been identified in individuals with autism spectrum disorder and intellectual disability. *JMJD1C* is also associated with congenital heart disease manifestation in 22q11.2 deletion syndrome patients. Amongst KDM4s, there are only two reports – single nucleotide substitutions of *KDM4C* in upper aerodigestive tract cancer and age of menarche. Mutations of *KDM5B*, *KDM5C* and *KDM6B* have been associated with neurodevelopment and a global developmental delay (Table 1; Supplementary Table 1). In particular, *KDM5C* is well recognised as an X-linked intellectual disability gene that is highly expressed in neural tissue. Mutations in PHD Finger Protein 8 (*PHF8*) are also associated with X-linked mental retardation and often accompanied by cleft lip/palate or autism. The phenotypes of *KDM5C* or *PHF8* mutations in humans are reflected by the deletion of these genes in mice (Table 1). On the other hand, *KDM6A* mutations are frequently found in individuals with Kabuki syndrome (KS), a genetic disease with developmental delay and congenital anomalies, (Table 1) highlighting the role of *KDM6A* in development. In addition to mutation listed in Supplementary Table 1, others have reported gross deletions, gross duplications, or chromosomal rearrangement in patients with KS or KS-like clinical manifestations [256,258,285-287]. However, whether the phenotypes observed are due to loss of demethylase activity solely is currently unknown.

Overall, the presence and connections of HIFs or dioxygenase mutations in human disorders and the knockout studies demonstrate the essential roles of these genes.

**Conclusion and future perspectives**

As our understanding of the cellular response to hypoxia advances, new aspects continue to unravel. The role of oxygen has surfaced as far broader than just an acceptor molecule in oxidative phosphorylation in the mitochondria. Through acting as a co-factor for diverse and functionally important enzymes, oxygen is mechanistically identified as a potent signalling molecule in cells. The emerging focus of the field includes new aspects of chromatin regulation, RNA biology and broad regulation of protein post-translational modifications directly controlled by oxygen levels. This advanced understanding in conjunction with development of novel therapeutic chemicals targeting dioxygenases should provide not only exciting new biological insights, but also better treatments for patients suffering from a range of diseases. One area of technological advancement that will greatly progress the field is the adaptation of novel and unbiased quantitative techniques for measuring chromatin structure, transcriptional output, proteomic changes and cellular behaviour. These approaches may provide resolution to some of the persisting major questions pertaining mechanisms controlling gene expression in response to hypoxia.
References


76. Singleton, R.S.; Liu-Yi, P.; Formenti, F.; Ge, W.; Sekirnik, R.; Fischer, R.; Adam, J.; Pollard, P.J.; Wolf, A.; Thalhammer, A., et al. Ogfod1 catalyzes prolyl hydroxylation of rps23 and is


**Competing Interests**

The authors declare no competing interests.

**Acknowledgements**

This work was supported by the Wellcome Trust (206293/Z/17/Z) and the University of Liverpool.

**Related Links**

Supplementary Table 1 and references.

**Display items**

Tables: 1

Figures: 6

Boxes: 1

**Glossary:**

Chromatin is a complex of DNA and proteins that forms chromosomes within the nucleus of eukaryotic cells.
Epigenetics- Reversible modifications to chromatin, typically referring to DNA and histones, which can alter gene expression.

IRES- Internal ribosome entry site (IRES) elements are RNA regions that recruit the translation machinery internally.